OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod
PremiumCompany AnnouncementsOKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod
2M ago
Okyo Pharma announces OK-101 officially assigned USAN, urcosimod
Premium
The Fly
Okyo Pharma announces OK-101 officially assigned USAN, urcosimod
2M ago
Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges
Premium
Ratings
Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges
2M ago
OKYO Pharma Secures $1.4 Million to Boost Ophthalmic Innovations
PremiumCompany AnnouncementsOKYO Pharma Secures $1.4 Million to Boost Ophthalmic Innovations
2M ago
Okyo Pharma receives $1.4M in non-dilutive financing
Premium
The Fly
Okyo Pharma receives $1.4M in non-dilutive financing
2M ago
OKYO Pharma to Highlight Innovations at BTIG Conference
Premium
Company Announcements
OKYO Pharma to Highlight Innovations at BTIG Conference
4M ago
Okyo starts screening, recruitment of patients for Phase 2 trial of OK-101
PremiumThe FlyOkyo starts screening, recruitment of patients for Phase 2 trial of OK-101
6M ago
OKYO Pharma Chairman Boosts Stake, Advances Trials
Premium
Company Announcements
OKYO Pharma Chairman Boosts Stake, Advances Trials
7M ago
Okyo Pharma announces acquisition of shares by chairman
Premium
The Fly
Okyo Pharma announces acquisition of shares by chairman
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100